retatrutide clinical trial south africa Trials Retatrutide, Eli Lilly's next obesity

StatPearls - NCBI Bookshelf

Retatrutide may suit individuals seeking significant, medically supervised weight loss who are interested in an emerging, next-generation peptide therapy

Hims & Hers trades at roughly 3.7 times sales, above the broader healthcare industry average of about 1.5 times but below the peer group average of about 4.2 times in the digital health space

The start low, go slow approach is standard across the GLP-1 drug family because rapid titration produces severe nausea

However, compounded versions are not FDA-approved, and quality, safety, and effectiveness may differ from branded products

C., and Xu R., Association of semaglutide with risk of suicidal ideation in a real-world cohort, Nat Med, Jan